6 August 2019
SpeeDx Raise US $15 million Equity from Northpond Ventures
Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets....
16 July 2019
Health Canada clears ResistancePlus® MG
This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy...
24 June 2019
SpeeDx sign collaboration agreement with GSK
SpeeDx signed a collaboration agreement with GSK to provide tests and custom test development to support antibiotic clinical trials...
13 June 2019
FDA Grant Breakthrough Designation for ResistancePlus® GC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation for ResistancePlus® GC - expediting the path towards clearance....
14 May 2019
PlexPCR® RespiVirus receives TGA clearance for sale in Australia
PlexPCR® RespiVirus received clearance from the Australian Therapeutic Goods Administration (TGA), bringing much needed workflow advantages in time for the...
3 May 2019
Study gauges impact of genotyping on gonorrhea treatment
Dr. Klausner, a clinical professor at UCLA, shares the details of his work with genotypic testing for ciprofloxacin susceptibility in...